BA
PTGX icon

Bellwether Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Bellwether Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,630
Closed -$241K – 596
2021
Q3 		$241K Buy
+13,630
New +$581K 0.08% 138

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bellwether Advisors's PTGX Position: Q4 2021 in Review

Bellwether Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 13,630 shares — an estimated $241K sold.

Bellwether Advisors first reported a position in PTGX in Q3 2021 and held it in 1 quarter. The position peaked at $241K in Q3 2021. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

  • Bellwether Advisors reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bellwether Advisors sold 13,630 Protagonist Therapeutics shares in Q4 2021, an estimated $241K.
  • Bellwether Advisors first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 1 quarter.
  • Bellwether Advisors's Protagonist Therapeutics position peaked at $241K in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on Bellwether Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.